Onkologie. 2017:11(5):224-226 | DOI: 10.36290/xon.2017.042

The clinical relevance of C-reactive protein in oncogynecology

Tomáš Cacek, Monika Náležinská, Josef Chovanec
Oddělení gynekologické onkologie, Klinika operační onkologie MOÚ a LF Masarykovy univerzity Brno

The review article discusses the possibilities of using C-reactive protein levels not only in its most frequent indication (differentialdiagnosis of acute inflammation in the body), but also analyzes new options for its use in oncology patients within prognostic scoringsystems, the benefits of linking with other biomarkers, or seeking its use as a marker of adaptive immune responses after chemotherapy.

Keywords: C-reactive protein, oncology, inflammation, Glasgow prognostic score

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cacek T, Náležinská M, Chovanec J. The clinical relevance of C-reactive protein in oncogynecology. Onkologie. 2017;11(5):224-226. doi: 10.36290/xon.2017.042.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Laňková J, Brodská H, Springer D, et al. Diagnostika CRP. Ústav všeobecného lékařství, 1. LF UK v Praze, Dostupný z https://www.euni.cz.
    2. Zima T. Laboratorní diagnostika. 2. vyd. Praha, Galén a Karolinum. 2007: 906 s.
    3. Liu Y, Chen S, Zheng C, et al. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017; 17(1): 285. Go to original source... Go to PubMed...
    4. McSorley MA, Alberg AJ, Allen DS, et al. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol. 2007; 109(4): 933-941. Go to original source...
    5. Utsumi F, Kajiyama H, Niimi K, et al. Clinical significance and predicting indicators of post-cancer-treatment survival in terminally ill patients with ovarian cancer. J Obstet Gynaecol Res. 2017; 43(2): 365-370. Go to original source...
    6. Madondo MT, Tuyaerts S, Turnbull BB, et al. Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancerpatients: a study of potential oscillatory behaviour and correlations. J Transl Med. 2014; 12: 179. Go to original source... Go to PubMed...
    7. Gorisek B, Miksić NG, Krajnc P, et al. The role of procalcitonin in gynaecological surgery, J Int Med Res. 2009; 37(3): 918-926. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.